SCHEMBL26106100

SCHEMBL26106100

COc1cnc(-c2c(C3=CCC4(CC3)CCN(C=CC=O)CC4)n(C)c3ncnc(N)c23)nc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26108434 0.92 KCNH2 (0.30) —
SCHEMBL26107398 0.90 — —
SCHEMBL26107952 0.90 — —
SCHEMBL26108735 0.90 RET (0.31) —
SCHEMBL26105475 0.89 LRRK2 (0.32) —
SCHEMBL26108002 0.89 SRC (0.37) —
SCHEMBL26104690 0.88 — —
SCHEMBL26108491 0.88 — —
SCHEMBL26108342 0.88 — —
SCHEMBL26109317 0.86 SRC (0.41) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
Send feedback